Clinical Perspective and Translational Oncology of Liquid Biopsy
The term liquid biopsy (LB) refers to the study of circulating tumor cells, circulating tumors nucleic acids free of cells or contained in exosomes, and information about platelets associated with tumors. LB can be performed in different biofluids and allows the limitations of tissue biopsy to be ov...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/7/443 |
| _version_ | 1797563801517686784 |
|---|---|
| author | Diego Fernández-Lázaro Juan Luis García Hernández Alberto Caballero García Aurora Caballero del Castillo María Villaverde Hueso Juan Jesús Cruz-Hernández |
| author_facet | Diego Fernández-Lázaro Juan Luis García Hernández Alberto Caballero García Aurora Caballero del Castillo María Villaverde Hueso Juan Jesús Cruz-Hernández |
| author_sort | Diego Fernández-Lázaro |
| collection | DOAJ |
| description | The term liquid biopsy (LB) refers to the study of circulating tumor cells, circulating tumors nucleic acids free of cells or contained in exosomes, and information about platelets associated with tumors. LB can be performed in different biofluids and allows the limitations of tissue biopsy to be overcome offering possibilities of tumor identification reflecting in real time tumor heterogeneity. In addition, LB allows screening and early detection of cancer, real-time monitoring of therapy, stratification and therapeutic intervention, a therapeutic target and resistance mechanism, and a risk of metastatic relapse. Currently, LB has been shown to be effective for its application in different types of tumors including lung, colorectal, prostate, melanoma, breast and pancreatic cancer, by the determination and identification of biomarkers that with a high probability have the potential to change the way in which medical oncology could predict the course of the disease. These biomarkers make it possible to capture the heterogeneity of the cancer, monitor its clonal evolution, indicate new treatments or retreatments and evaluate the responses to different evolutionary and/or therapeutic pressures in the cancer disease. |
| first_indexed | 2024-03-10T18:47:22Z |
| format | Article |
| id | doaj.art-5304065890184e99a155a65e8d234c6b |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T18:47:22Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-5304065890184e99a155a65e8d234c6b2023-11-20T05:22:43ZengMDPI AGDiagnostics2075-44182020-06-0110744310.3390/diagnostics10070443Clinical Perspective and Translational Oncology of Liquid BiopsyDiego Fernández-Lázaro0Juan Luis García Hernández1Alberto Caballero García2Aurora Caballero del Castillo3María Villaverde Hueso4Juan Jesús Cruz-Hernández5Department of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus de Soria, 42003 Soria, SpainCancer Research Centre, University of Salamanca, 37007 Salamanca, SpainDepartment of Anatomy and Radiology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, SpainOncology Service, University Hospital of Salamanca, 37007 Salamanca, SpainDepartment of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus de Soria, 42003 Soria, SpainInstitute of Biomedical Research of Salamanca, University Hospital of Salamanca (IBSAL), 3007 Salamanca, SpainThe term liquid biopsy (LB) refers to the study of circulating tumor cells, circulating tumors nucleic acids free of cells or contained in exosomes, and information about platelets associated with tumors. LB can be performed in different biofluids and allows the limitations of tissue biopsy to be overcome offering possibilities of tumor identification reflecting in real time tumor heterogeneity. In addition, LB allows screening and early detection of cancer, real-time monitoring of therapy, stratification and therapeutic intervention, a therapeutic target and resistance mechanism, and a risk of metastatic relapse. Currently, LB has been shown to be effective for its application in different types of tumors including lung, colorectal, prostate, melanoma, breast and pancreatic cancer, by the determination and identification of biomarkers that with a high probability have the potential to change the way in which medical oncology could predict the course of the disease. These biomarkers make it possible to capture the heterogeneity of the cancer, monitor its clonal evolution, indicate new treatments or retreatments and evaluate the responses to different evolutionary and/or therapeutic pressures in the cancer disease.https://www.mdpi.com/2075-4418/10/7/443liquid biopsycancer detectionclinical practicemolecular profileminimal residual diseaseresponse monitoring |
| spellingShingle | Diego Fernández-Lázaro Juan Luis García Hernández Alberto Caballero García Aurora Caballero del Castillo María Villaverde Hueso Juan Jesús Cruz-Hernández Clinical Perspective and Translational Oncology of Liquid Biopsy Diagnostics liquid biopsy cancer detection clinical practice molecular profile minimal residual disease response monitoring |
| title | Clinical Perspective and Translational Oncology of Liquid Biopsy |
| title_full | Clinical Perspective and Translational Oncology of Liquid Biopsy |
| title_fullStr | Clinical Perspective and Translational Oncology of Liquid Biopsy |
| title_full_unstemmed | Clinical Perspective and Translational Oncology of Liquid Biopsy |
| title_short | Clinical Perspective and Translational Oncology of Liquid Biopsy |
| title_sort | clinical perspective and translational oncology of liquid biopsy |
| topic | liquid biopsy cancer detection clinical practice molecular profile minimal residual disease response monitoring |
| url | https://www.mdpi.com/2075-4418/10/7/443 |
| work_keys_str_mv | AT diegofernandezlazaro clinicalperspectiveandtranslationaloncologyofliquidbiopsy AT juanluisgarciahernandez clinicalperspectiveandtranslationaloncologyofliquidbiopsy AT albertocaballerogarcia clinicalperspectiveandtranslationaloncologyofliquidbiopsy AT auroracaballerodelcastillo clinicalperspectiveandtranslationaloncologyofliquidbiopsy AT mariavillaverdehueso clinicalperspectiveandtranslationaloncologyofliquidbiopsy AT juanjesuscruzhernandez clinicalperspectiveandtranslationaloncologyofliquidbiopsy |